Visible skin concerns — wrinkles, pigmentation, redness, dark circles, eye bags — are typically discussed as though they belong to the same category of problem. They do not. Each one is the downstream expression of a distinct biological mechanism, involving different cells, different molecular pathways, and different upstream drivers. Treating them interchangeably, or applying a single-formula approach, is not imprecision by chance. It is imprecision by design — the inevitable outcome of an industry that categorises skin by type rather than by biology.
What follows is a brief molecular account of each concern. Not an exhaustive textbook. A practical orientation — the kind that changes what questions you ask, and what answers you accept.
Wrinkles and Laxity: The ECM Story
The structural integrity of the face depends on the Extra Cellular Matrix (ECM) — the protein scaffold within the dermis that provides both support and resilience. Wrinkles and laxity are the visible consequence of ECM breakdown outpacing repair.
The primary drivers are Matrix Metalloproteinase (MMP) enzyme activity, stimulated by Ultraviolet (UV) radiation and Reactive Oxygen Species (ROS), and the progressive accumulation of senescent fibroblasts — dermal cells that have lost their ability to synthesise new collagen. Cortisol suppresses collagen synthesis. Glycation cross-links and stiffens existing fibres. The result, over years, is a dermal architecture that can no longer support the overlying skin as it once did.
The protocol implication: addressing wrinkles at the surface without targeting MMP activity and collagen synthesis upstream is addressing the symptom, not the cause.
Pigmentation and Uneven Tone: The Melanogenesis Pathway
Pigmentation is, at its most fundamental level, a genetic and hormonal story. The enzyme tyrosinase — the rate-limiting catalyst of melanin production — is activated by a cascade that begins at the Melanocortin 1 Receptor (MC1R), proceeds through Melanocyte Inducing Transcription Factor (MITF), and culminates in tyrosinase expression within the melanocyte.
UV exposure triggers this cascade. So do hormonal fluctuations — particularly oestrogen and progesterone — which is why pregnancy and oral contraceptive use often precipitate new pigmentation. Inflammation activates it too. The result is melanin synthesis and transfer to surrounding keratinocytes, which retain it as visible pigment.
What makes this complex is the genetic dimension. MC1R polymorphisms — genetic variants that alter receptor sensitivity — differ significantly across populations. This means that two individuals with identical UV exposure may have dramatically different pigmentation responses. A precision approach accounts for this genetic architecture. A generalised one cannot.
Redness and Sensitivity: The Neuro-Immune Pathway
Persistent facial redness is not — in most cases — a surface-level problem or a simple sensitivity. It reflects chronic activation of the skin's innate immune system, mediated through a pathway involving Toll-Like Receptor 2 (TLR2) and its downstream signalling cascades.
TLR2 activation triggers the release of cathelicidin antimicrobial peptides (including LL-37), which produce vasodilation, neurogenic inflammation, and the recruitment of immune cells to the dermis. In susceptible individuals, this pathway can become tonically overactivated — producing chronic redness, heat, and reactivity to stimuli that would not affect unaffected skin.
Topical products that address the barrier without targeting the neuro-immune cascade can reduce irritation but cannot resolve the underlying activation state. A protocol calibrated to TLR2/LL-37 pathway modulation — through specific anti-inflammatory actives and barrier repair — addresses the actual mechanism.
Dark Circles: The Periorbital Vascular and Structural Triad
Dark circles are almost never a single-mechanism concern. In most individuals, they represent a combination of three overlapping phenomena: increased visibility of the orbicularis oculi muscle and superficial vasculature through a progressively thinning dermis; post-inflammatory pigmentation deposited in the periorbital skin; and the shadow cast by volume loss in the tear trough — the structural depression that develops as orbital fat redistributes with age.
Each component has a different target. Vascular dark circles respond to interventions that reduce the visibility of underlying vasculature. Pigmented dark circles respond to melanogenesis pathway inhibition. Structural dark circles respond to volume restoration — either through filler or, where anatomy requires, through surgical correction of the underlying fat compartment position.
Conflating them into a single "dark circle" category produces protocols that address one component while ignoring the other two.
Eye Bags and Puffiness: Lymphatic Insufficiency and Fat Redistribution
The lower eyelid fullness that is colloquially referred to as eye bags has two primary biological drivers.
The first is lymphatic insufficiency — the progressive reduction in lymphatic drainage capacity in the periorbital region that accompanies ageing. When lymphatic function declines, fluid accumulates in the loose connective tissue of the lower lid, producing intermittent to persistent puffiness. This is the component that fluctuates with sleep quality, salt intake, and posture.
The second is orbital fat redistribution — not simply fat accumulation, but a change in the position and behaviour of the fat pockets behind the orbital septum. As the septum weakens and the retaining ligaments of the lower lid relax with age, these fat pockets herniate forward, producing the fixed structural fullness of true lower lid bags. This component does not respond to lymphatic drainage or topical intervention. It requires surgical correction — specifically, lower lid blepharoplasty — to address definitively.
Understanding which component is driving the presentation determines whether the right response is a protocol, a procedure, or both.
The Common Thread
Each of these concerns shares one principle: the visible presentation is the endpoint of a process, not the process itself. The most meaningful clinical work — the work that actually changes the trajectory rather than managing the expression — happens at the level of the mechanism.
That is the orientation from which every protocol at this practice, and every recommendation within the SKNCODE™ platform, is built.